SCHEMBL11946085

SCHEMBL11946085

O=c1c(OC2CCCC2)c(N2CCC(S(=O)(=O)N(Cc3ccccc3)c3ccccc3)CC2)cnn1-c1cccc(F)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ GRM2 Q14416 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ NCOA2 Q15596 1/20 0.36
▸ NCOA1 Q15788 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ NCOA3 Q9Y6Q9 1/20 0.36
▸ NPC1 O15118 4/20 0.35
▸ RAB9A P51151 4/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HIF1A Q16665 1/20 0.34
▸ EPAS1 Q99814 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ ALDH1A1 P00352 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946497 0.92 NPC1 (0.36) KMT2APOLBCYP3A4CYP2C19PPARG
SCHEMBL11945125 0.82 MAPT (0.46) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11946088 0.82 POLB (0.40) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944021 0.81 MAPT (0.46) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11943998 0.80 POLB (0.47) MEN1KMT2APOLBCYP3A4CYP2C19
SCHEMBL11945120 0.79 MAPT (0.52) MEN1KMT2APOLBCYP3A4CYP2C19
SCHEMBL11943823 0.79 TRPC5 (0.41) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL17057874 0.79 NPC1 (0.40) KMT2AL3MBTL1POLBCYP3A4CYP2C19
SCHEMBL17058333 0.79 POLB (0.38) MEN1KMT2APOLBCYP3A4CYP2C19
SCHEMBL11945823 0.79 POLB (0.50) KMT2APOLBCYP3A4CYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MEN1 1830/4885KMT2A 3312/4885L3MBTL1 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback